All such hyperglycemia‐associated treatment disruptions occurred in patients exposed to AKT (5%), α(13%), or pan‐PI3K inhibitors (5%), with none in patients exposed to PI3K inhibitors specific for isoforms other than α. Here, AKT1 is linked to Hyperglycemia.